Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ocrelizumab for the Treatment of Multiple Sclerosis

Trial Profile

Ocrelizumab for the Treatment of Multiple Sclerosis

Phase of Trial: Phase II

Latest Information Update: 01 Dec 2018

At a glance

  • Drugs Ocrelizumab (Primary) ; Fingolimod; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2018 New trial record
    • 14 Nov 2018 Results assessing efficacy of Ocrelizumab for the treatment of Multiple Sclerosis, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top